24,25-dihydroxycholecalciferol
24-Hydroxycalcidiol (24,25-dihydroxy vitamin D3) is a circulating metabolite of vitamin D3. 24,25(OH)2D3 functions by activation of Vitamin D receprtor and promotion of ostecalcin expression, but is less effective than other D3 metabolite, 1alpha,25(OH)2D3. There is conflicting evidence on efffect of 24-hydroxycalcidiol on bone metabolism. In several animal studies it was demonstrated that 24-hydroxycalcidiol was able to stimulate calcification of bone and restore the reduction in bone mineral apposition rate. However, no beneficial effect of 24R,25(OH)2D3 treatment of postmenapausal women on bone mineral density or bone loss and calcium metabolism were observed. — NCATS
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Earliest trial started Sep 20, 2021 (NCT05560919)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Vitamin D receptorAGONIST
VDR agonist
Chemistry & pharmacology
SMILES
C[C@H](CCC(O)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C3\C[C@@H](O)CCC3=C- Mol. weight
- 416.6365 g/mol
Oral
No
Parenteral
No
Topical
No
Sources
- NCATS0AXX2V8L5Z ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05560919 | Phase 2/Phase 3 (Phase 3) | Sep 20, 2021 | Tishreen University |
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Tishreen University | Academic/Hospital | 1 | 1 | 1 | 2021 |